Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • A Phase Ib/Il, Open-Label, Multicenter, Randomized Platform Study Evaluating the Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients with Surgically Resectable Hepatoceullular Carcinoma (Morpheus-NEO HCC)

    Cancer Categories
    • Gastrointestinal (GI)
    Karmanos Trial ID
    • 2023-025
    NCT ID
    • NCT05908786
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I/II
    Principal Investigator

    Objective:

    Primary Efficacy Objective:

    • To evaluate the efficacy of neoadjuvant immunotherapy-based treatment combinations

    Secondary Efficacy Objective:

    • To evaluate the efficacy of neoadjuvant immunotherapy-based treatment combinations

    Safety Objectives:

    • To evaluate the safety and tolerability of neoadjuvant immunotherapy-based treatment combinations
    • To assess surgical feasibility, outcomes, morbidity, and mortality in participants receiving neoadjuvant immunotherapy-based treatment combinations
  • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266